Literature DB >> 33748935

In silico modeling of PAX8-PPARγ fusion protein in thyroid carcinoma: influence of structural perturbation by fusion on ligand-binding affinity.

Kaori Sakaguchi1, Yoshio Okiyama2, Shigenori Tanaka3.   

Abstract

Paired box 8 (PAX8)-peroxisome proliferator-activated receptor γ (PPARγ) rearrangement is believed to play an important role in tumorigenesis of PAX8-PPARγ fusion protein (PPFP) thyroid carcinomas, while without establishing any standard treatment, including drugs. Although PPFP is a potential promising target for therapeutic agents, the three-dimensional (3D) structure and functions have not yet been experimentally elucidated. In this study, we aimed to construct the 3D structure of PPFP and to aid in the development of therapies that can target PPFP for thyroid carcinomas. The 3D structure of PPFP was constructed by homology modeling based on crystallographic structure data. To validate the modeled structure, we analyzed the thermal fluctuations by molecular dynamics simulations and predicted the physical properties using bioinformatic analyses. We found that the modeled structure was stable under hydrated conditions and had features indicating the actual existence of the structure. Furthermore, the binding free energies of the ligand rosiglitazone with PPARγ and PPFP were evaluated by the molecular mechanics-Poisson-Boltzmann surface area method. We found that rosiglitazone has different binding affinities for the same binding pockets of PPARγ and PPFP, and the optimal compound for PPFP can differ from that of PPARγ. This suggests the need for the development of drugs targeting PPFP that allow for the fusion, rather than focusing on the PPARγ side of PPFP and searching for the best compounds for that pocket. Our findings are expected to lead to the development of new therapies for thyroid tumors.

Entities:  

Keywords:  Follicular thyroid neoplasia; MM-PBSA; Molecular dynamics simulation; Molecular modeling; PAX8–PPARγ fusion protein; Protein–ligand binding

Mesh:

Substances:

Year:  2021        PMID: 33748935     DOI: 10.1007/s10822-021-00381-x

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  30 in total

1.  PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro.

Authors:  E D Rosen; P Sarraf; A E Troy; G Bradwin; K Moore; D S Milstone; B M Spiegelman; R M Mortensen
Journal:  Mol Cell       Date:  1999-10       Impact factor: 17.970

2.  PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected].

Authors:  T G Kroll; P Sarraf; L Pecciarini; C J Chen; E Mueller; B M Spiegelman; J A Fletcher
Journal:  Science       Date:  2000-08-25       Impact factor: 47.728

3.  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.

Authors:  Marcia S Brose; Christopher M Nutting; Barbara Jarzab; Rossella Elisei; Salvatore Siena; Lars Bastholt; Christelle de la Fouchardiere; Furio Pacini; Ralf Paschke; Young Kee Shong; Steven I Sherman; Johannes W A Smit; John Chung; Christian Kappeler; Carol Peña; István Molnár; Martin J Schlumberger
Journal:  Lancet       Date:  2014-04-24       Impact factor: 79.321

Review 4.  Pax genes: regulators of lineage specification and progenitor cell maintenance.

Authors:  Judith A Blake; Melanie R Ziman
Journal:  Development       Date:  2014-02       Impact factor: 6.868

Review 5.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

6.  On the prevalence of the PAX8-PPARG fusion resulting from the chromosomal translocation t(2;3)(q13;p25) in adenomas of the thyroid.

Authors:  Markus Klemke; Norbert Drieschner; Anne Laabs; Volkhard Rippe; Gazanfer Belge; Jörn Bullerdiek; Wolfgang Sendt
Journal:  Cancer Genet       Date:  2011-06

7.  Comparative proteomic analysis to identify the novel target gene of angiotensin II in adrenocortical H295R cells.

Authors:  Ryo Ito; Hiroki Shima; Koji Masuda; Ikuko Sato; Hiroki Shimada; Atsushi Yokoyama; Katsuhiko Shirahige; Kazuhiko Igarashi; Akira Sugawara
Journal:  Endocr J       Date:  2020-12-26       Impact factor: 2.349

8.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

Authors:  Martin Schlumberger; Makoto Tahara; Lori J Wirth; Bruce Robinson; Marcia S Brose; Rossella Elisei; Mouhammed Amir Habra; Kate Newbold; Manisha H Shah; Ana O Hoff; Andrew G Gianoukakis; Naomi Kiyota; Matthew H Taylor; Sung-Bae Kim; Monika K Krzyzanowska; Corina E Dutcus; Begoña de las Heras; Junming Zhu; Steven I Sherman
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

9.  Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.

Authors:  Samuel A Wells; Bruce G Robinson; Robert F Gagel; Henning Dralle; James A Fagin; Massimo Santoro; Eric Baudin; Rossella Elisei; Barbara Jarzab; James R Vasselli; Jessica Read; Peter Langmuir; Anderson J Ryan; Martin J Schlumberger
Journal:  J Clin Oncol       Date:  2011-10-24       Impact factor: 44.544

10.  Pax8 has a key role in thyroid cell differentiation.

Authors:  M Pasca di Magliano; R Di Lauro; M Zannini
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.